• Je něco špatně v tomto záznamu ?

Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition

A. Misiachna, B. Svobodova, J. Netolicky, M. Chvojkova, L. Kleteckova, L. Prchal, M. Novak, M. Hrabinova, T. Kucera, L. Muckova, Z. Moravcova, JZ. Karasova, J. Pejchal, F. Blazek, D. Malinak, K. Hakenova, BH. Krausova, M. Kolcheva, M. Ladislav,...

. 2024 ; 266 (-) : 116130. [pub] 20240107

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007126

Tacrine (THA), a long withdrawn drug, is still a popular scaffold used in medicinal chemistry, mainly for its good reactivity and multi-targeted effect. However, THA-associated hepatotoxicity is still an issue and must be considered in drug discovery based on the THA scaffold. Following our previously identified hit compound 7-phenoxytacrine (7-PhO-THA), we systematically explored the chemical space with 30 novel derivatives, with a focus on low hepatotoxicity, anticholinesterase action, and antagonism at the GluN1/GluN2B subtype of the NMDA receptor. Applying the down-selection process based on in vitro and in vivo pharmacokinetic data, two candidates, I-52 and II-52, selective GluN1/GluN2B inhibitors thanks to the interaction with the ifenprodil-binding site, have entered in vivo pharmacodynamic studies. Finally, compound I-52, showing only minor affinity to AChE, was identified as a lead candidate with favorable behavioral and neuroprotective effects using open-field and prepulse inhibition tests, along with scopolamine-based behavioral and NMDA-induced hippocampal lesion models. Our data show that compound I-52 exhibits low toxicity often associated with NMDA receptor ligands, and low hepatotoxicity, often related to THA-based compounds.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007126
003      
CZ-PrNML
005      
20240423155735.0
007      
ta
008      
240412e20240107fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2024.116130 $2 doi
035    __
$a (PubMed)38218127
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic; Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, 128 43, Prague, Czech Republic
245    10
$a Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition / $c A. Misiachna, B. Svobodova, J. Netolicky, M. Chvojkova, L. Kleteckova, L. Prchal, M. Novak, M. Hrabinova, T. Kucera, L. Muckova, Z. Moravcova, JZ. Karasova, J. Pejchal, F. Blazek, D. Malinak, K. Hakenova, BH. Krausova, M. Kolcheva, M. Ladislav, J. Korabecny, J. Pahnke, K. Vales, M. Horak, O. Soukup
520    9_
$a Tacrine (THA), a long withdrawn drug, is still a popular scaffold used in medicinal chemistry, mainly for its good reactivity and multi-targeted effect. However, THA-associated hepatotoxicity is still an issue and must be considered in drug discovery based on the THA scaffold. Following our previously identified hit compound 7-phenoxytacrine (7-PhO-THA), we systematically explored the chemical space with 30 novel derivatives, with a focus on low hepatotoxicity, anticholinesterase action, and antagonism at the GluN1/GluN2B subtype of the NMDA receptor. Applying the down-selection process based on in vitro and in vivo pharmacokinetic data, two candidates, I-52 and II-52, selective GluN1/GluN2B inhibitors thanks to the interaction with the ifenprodil-binding site, have entered in vivo pharmacodynamic studies. Finally, compound I-52, showing only minor affinity to AChE, was identified as a lead candidate with favorable behavioral and neuroprotective effects using open-field and prepulse inhibition tests, along with scopolamine-based behavioral and NMDA-induced hippocampal lesion models. Our data show that compound I-52 exhibits low toxicity often associated with NMDA receptor ligands, and low hepatotoxicity, often related to THA-based compounds.
650    _2
$a lidé $7 D006801
650    12
$a neuroprotektivní látky $x farmakologie $x terapeutické užití $7 D018696
650    _2
$a receptory N-methyl-D-aspartátu $7 D016194
650    _2
$a takrin $x chemie $7 D013619
650    _2
$a cholinesterasové inhibitory $x chemie $7 D002800
650    _2
$a vazebná místa $7 D001665
650    _2
$a cholinesterasy $7 D002802
650    12
$a lékové postižení jater $7 D056486
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    12
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    12
$a piperidiny $7 D010880
655    _2
$a časopisecké články $7 D016428
700    1_
$a Svobodova, Barbora $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Netolicky, Jakub $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic
700    1_
$a Chvojkova, Marketa $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Kleteckova, Lenka $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Prchal, Lukas $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Novak, Martin $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Hrabinova, Martina $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Muckova, Lubica $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Moravcova, Zuzana $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika, Heyrovskeho 1203, 50005, Hradec Králové, Czech Republic
700    1_
$a Karasova, Jana Zdarova $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Pejchal, Jaroslav $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Blazek, Filip $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03, Hradec Kralove, Czech Republic
700    1_
$a Malinak, David $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03, Hradec Kralove, Czech Republic
700    1_
$a Hakenova, Kristina $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Ruska 87, 100 00, Prague 10, Czech Republic
700    1_
$a Krausova, Barbora Hrcka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic
700    1_
$a Kolcheva, Marharyta $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic
700    1_
$a Ladislav, Marek $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic
700    1_
$a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Pahnke, Jens $u Department of Neuro-/Pathology, University of Oslo & Oslo University Hospital, Oslo, Norway
700    1_
$a Vales, Karel $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Ruska 87, 100 00, Prague 10, Czech Republic
700    1_
$a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic. Electronic address: martin.horak@iem.cas.cz
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 266 (20240107), s. 116130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38218127 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155731 $b ABA008
999    __
$a ok $b bmc $g 2081240 $s 1216893
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 266 $c - $d 116130 $e 20240107 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace